Tilray Medical has introduced its inaugural line of medical cannabis edibles, known as Good Supply Pastilles, to the Australian market. This development signifies the company's foray into offering edible cannabis treatments in the region. These pastilles are designed to cater to patients seeking a sugar-free, vegan-friendly option for their medical needs.
The launch reflects Tilray's (TLRY, Financial) commitment to expanding its product offerings and meeting diverse patient preferences. By providing an alternative form of cannabis medication, Tilray aims to enhance the accessibility and flexibility of treatment options for Australian patients.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for Tilray Brands Inc (TLRY, Financial) is $1.28 with a high estimate of $2.50 and a low estimate of $0.60. The average target implies an upside of 168.07% from the current price of $0.48. More detailed estimate data can be found on the Tilray Brands Inc (TLRY) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, Tilray Brands Inc's (TLRY, Financial) average brokerage recommendation is currently 2.7, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Tilray Brands Inc (TLRY, Financial) in one year is $1.92, suggesting a upside of 303.53% from the current price of $0.4758. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Tilray Brands Inc (TLRY) Summary page.
